Method for Preparing 3,6-Anhydro-L-Galactose, And Use Thereof

Abstract

The present invention relates to a method for preparing 3,6-anhydro-L-galactose, and use thereof. More specifically, 3,6-anhydro-L-galactose, which is a monosaccharide constituting agar, is produced in a high yield through chemical and enzymatic methods, and the physiological activities thereof such as whitening, moisturizing, antioxidant, anti-inflammatory activities and the like are displayed, thereby enabling industrial use thereof.

What is claimed is: 
     
         1 . A cosmetic composition for skin whitening or moisturizing, comprising 3,6-anhydro-L-galactose represented by the following Formula 1: 
       
         
           
           
               
               
           
         
       
     
     
         2 . The cosmetic composition of  claim 1 , wherein the 3,6-anhydro-L-galactose is prepared by:
 preparing an agarooligosaccharide by allowing agarose to react with a weak acid at a concentration of 0.5 to 60% (w/v) at a temperature of 40 to 150° C. and a rotary speed of 100 to 200 rpm for 30 minutes to 6 hours; and   allowing the agarooligosaccharide to react with an agarose-degrading enzyme and a neoagarobiose hydrolase at a temperature of 20 to 40° C. and a rotary speed of 0 to 200 rpm for 30 minutes to 7 days.   
     
     
         3 . The cosmetic composition of  claim 2 , wherein the weak acid is at least one selected from the group consisting of acetic acid, formic acid, succinic acid, citric acid, malic acid, maleic acid, and oxalic acid. 
     
     
         4 . The cosmetic composition of  claim 2 , wherein the agarose-degrading enzyme is represented by an amino acid sequence set forth in SEQ ID NO: 1. 
     
     
         5 . The cosmetic composition of  claim 2 , wherein the neoagarobiose hydrolase is represented by an amino acid sequence set forth in SEQ ID NO: 3. 
     
     
         6 . A pharmaceutical composition for preventing or treating a skin pigmentation disease, comprising 3,6-anhydro-L-galactose represented by the following Formula 1: 
       
         
           
           
               
               
           
         
       
     
     
         7 . The pharmaceutical composition of  claim 6 , wherein the skin pigmentation disease is locally advanced due to an increase in synthesis of a melanin pigment, and is at least one selected from the group consisting of chloasma, freckles, lentigo, nevi, pigmentation caused by use of drugs, post-inflammatory pigmentation, and hyperpigmentation occurring on dermatitis. 
     
     
         8 . The pharmaceutical composition of  claim 6 , wherein the 3,6-anhydro-L-galactose is prepared by:
 preparing an agarooligosaccharide by allowing agarose to react with a weak acid at a concentration of 0.5 to 60% (w/v) at a temperature of 40 to 150° C. and a rotary speed of 100 to 200 rpm for 30 minutes to 6 hours; and   allowing the agarooligosaccharide to react with an agarose-degrading enzyme and a neoagarobiose hydrolase at a temperature of 20 to 40° C. and a rotary speed of 0 to 200 rpm for 30 minutes to 7 days.   
     
     
         9 . The pharmaceutical composition of  claim 8 , wherein the weak acid is at least one selected from the group consisting of acetic acid, formic acid, succinic acid, citric acid, malic acid, maleic acid, and oxalic acid. 
     
     
         10 . The pharmaceutical composition of  claim 8 , wherein the agarose-degrading enzyme is represented by an amino acid sequence set forth in SEQ ID NO: 1. 
     
     
         11 . The pharmaceutical composition of  claim 8 , wherein the neoagarobiose hydrolase is represented by an amino acid sequence set forth in SEQ ID NO: 3. 
     
     
         12 . A pharmaceutical composition for preventing or treating an inflammatory disease, comprising 3,6-anhydro-L-galactose represented by the following Formula 1: 
       
         
           
           
               
               
           
         
       
     
     
         13 . The pharmaceutical composition of  claim 12 , wherein the 3,6-anhydro-L-galactose is prepared by:
 preparing an agarooligosaccharide by allowing agarose to react with a weak acid at a concentration of 0.5 to 60% (w/v) at a temperature of 40 to 150° C. and a rotary speed of 100 to 200 rpm for 30 minutes to 6 hours; and   allowing the agarooligosaccharide to react with an agarose-degrading enzyme and a neoagarobiose hydrolase at a temperature of 20 to 40° C. and a rotary speed of 0 to 200 rpm for 30 minutes to 7 days.   
     
     
         14 . The pharmaceutical composition of  claim 13 , wherein the weak acid is at least one selected from the group consisting of acetic acid, formic acid, succinic acid, citric acid, malic acid, maleic acid, and oxalic acid. 
     
     
         15 . The pharmaceutical composition of  claim 13 , wherein the agarose-degrading enzyme is represented by an amino acid sequence set forth in SEQ ID NO: 1. 
     
     
         16 . The pharmaceutical composition of  claim 13 , wherein the neoagarobiose hydrolase is represented by an amino acid sequence set forth in SEQ ID NO: 3. 
     
     
         17 . A method for preparing 3,6-anhydro-L-galactose, comprising:
 preparing an agarooligosaccharide by allowing agarose to react with a weak acid at a concentration of 0.5 to 60% (w/v) at a temperature of 40 to 150° C. and a rotary speed of 100 to 200 rpm for 30 minutes to 6 hours; and   allowing the agarooligosaccharide to react with an agarose-degrading enzyme and a neoagarobiose hydrolase at a temperature of 20 to 40° C. and a rotary speed of 0 to 200 rpm for 30 minutes to 7 days.   
     
     
         18 . The method of  claim 17 , wherein the weak acid is at least one selected from the group consisting of acetic acid, formic acid, succinic acid, citric acid, malic acid, maleic acid, and oxalic acid. 
     
     
         19 . The method of  claim 17 , wherein the agarose-degrading enzyme is represented by an amino acid sequence set forth in SEQ ID NO: 1. 
     
     
         20 . The method of  claim 17 , wherein the neoagarobiose hydrolase is represented by an amino acid sequence set forth in SEQ ID NO: 3.